C3:CH50 ratio as a proposed composite marker for Eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.

C3:CH50 ratio as a proposed composite marker for Eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results. J Immunoassay Immunochem. 2016 Sep 12; Authors: Kerboua KE, Haiba F, Batouche D Abstract Treatment of atypical hemolytic uremic syndrome (aHUS) by the complement C5 inhibitor Eculizumab (Soliris(®)) is highly effective but unfortunately, associated with an economic pressure on the health care systems even in high incomes countries. Despite spacing infusions has been proposed as the unique solution to minimize this economic impact, no reliable laboratory assays are available to tailor such therapy optimization. To propose and evaluate a complement composite marker for eculizumab efficacy monitoring in aHUS. We have retrospectively analyzed complement profiles data of eight aHUS patients under eculizumab from the International Registry of HUS/Thrombotic Thrombocytopenia Purpura, and calculated a novel marker 'C3:CH50 ratio' by dividing C3 value by CH50 one for each sample during induction and maintenance periods. The results significance was compared to the currently used biomarkers for eculizumab tailoring. In contrary to the current biomarkers used for eculizumab efficacy monitoring like CH50 and soluble or deposit membrane attack complexes, 'C3:CH50 ratio' seems to be the most interesting one since its value at pre-Eculizumab dosage equaled 0.92± 0.2 while the post-Eculizumab one increased significantl...
Source: Journal of Immunoassay and Immunochemistry - Category: Biochemistry Tags: J Immunoassay Immunochem Source Type: research